Fidelity SPDR Advertisement
Home > Boards > US Listed > Medical - Drugs >

Human Genome Sciences, Inc (HGSI)

HGSI RSS Feed
Add HGSI Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 7/17/2014 9:20:50 AM - Followers: 26 - Board type: Free - Posts Today: 0

Human Genome Sciences

            HGSI Still Has Plenty of Room to Grow

July 20, 2009 3:31 PM ET 

 

 
Human Genome Sciences (NASDAQ:HGSI) is a biopharmaceutical company with a pipeline of novel protein and antibody drugs directed toward large markets that have significant unmet medical need.

HGS Home page:


 

 
{C}
Print E-mail
HUMAN GENOME SCIENCES AND NOVOZYMES ANNOUNCE AMENDMENT TO ALBUMIN FUSION LICENSE AGREEMENT

Rockville, Maryland and Nottingham, UK - May 7, 2009 - Human Genome Sciences, Inc. (NASDAQ: HGSI) and Novozymes Biopharma, a part of Novozymes (NASDAQ: NZYM B), today announced that they have amended an existing license agreement to allow both companies to expand application of their proprietary albumin fusion technology.

Under the amended agreement, HGS and Novozymes each has the opportunity to exclusively license and/or sublicense a number of albumin fusion proteins in exchange for royalties and other consideration. No existing HGS or Novozymes products or product rights, including rights licensed to other companies, are affected by these amendments. Financial or other terms of the agreement were not disclosed.

"Genetic fusion of therapeutic proteins to albumin can improve the pharmacology of the proteins, resulting in important benefits to patients," said Barry A. Labinger, Executive Vice President and Chief Commercial Officer, HGS. "For example, with certain therapeutic proteins, albumin fusion may make it possible to dose less frequently and reduce side effects associated with injections. We are pleased to work with Novozymes to broaden the application of albumin fusion technology to new classes of proteins and peptides."

Thomas Videbæk, Executive Vice President, Novozymes, said, "We are delighted to expand this license agreement with HGS. We license both the fusion protein and the yeast expression systems, which have been optimised for producing albumin fusion proteins as the solution that provides an efficacious half-life in patients. Our strength lies in the fact that we focus on solutions and that is why Novozymes is an ideal partner for the pharmaceutical industry. This enables Novozymes to continue to further develop albufuse®, our proprietary albumin fusion technology, and advance our existing and new partnerships."




5/21/2009

 
Human Genome Reports Positive Results For Long-Term Phase 2 Continuation Trial Of Benlysta In SLE Patients - Update
 
Human Genome Sciences Reveals Positive Trial Results Of Lupus Drug, Shares Up - Update
 
Human Genome Sciences Reveals Positive Long-Term Data For BENLYSTA In Patients With Active Systemic Lupus Erythematosus - Quick Facts
 
Human Genome Sciences - Racing To Cure Lupus
 
 
Human Genome Sciences Submits Biologics License Application For ABthrax To FDA -
(RTTNews) - Thursday, (5-21-09) biotechnology company Human Genome Sciences, Inc. (HGSI: News ) announced the submission of a Biologics License Application or BLA with the U.S. Food and Drug Administration or FDA related to human monoclonal antibody drug Abthrax for the treatment of inhalation anthrax.
Anthrax infection is caused by a spore-forming bacterium, Bacillus anthracis, which multiplies in the body and produces lethal toxins.
 
The Rockville, Maryland-based company said the BLA was submitted on the results of the efficacy tests of raxibacumab carried out on rabbits and monkeys. The results exhibited a survival benefit in both rabbits and monkeys, which is needed for launching the efficacy of new drugs used to counter bioterrorism. The submission also includes the results of safety studies of raxibacumab conducted in healthy human volunteers.
 
Raxibacumab is a first-in-class treatment for anthrax, and is being developed under a contract entered into in 2006 with the Biomedical Advanced Research and Development Authority or BARDA.
 
In the first quarter of 2009, under the BARDA contract, HGS achieved its first product sales by initiating the delivery of 20,000 doses of raxibacumab to the U.S. Strategic National Stockpile for emergency use in the treatment of inhalation anthrax.
 
HGS said it generated revenue of $153.8 million in raxibacumab in the first quarter, including $127.8 million in product sales. The company has now completed delivery and expects to recognize at least $8.0 million in additional raxibacumab revenue in the second quarter of 2009. 
 
Commenting on the submission, HGS' senior vice president, development and regulatory affairs, Sally Bolmer said, "Based on the results of our efficacy and safety studies, we believe raxibacumab has the potential to be an important new treatment for inhalation anthrax. In addition, the raxibacumab BLA is the first HGS has submitted, so it represents a significant milestone for our company."

 

 

RELATED STORY LINKS

 

 

Human Genome Shares Rally on Drug Trial At Wall Street Journal, 6/11/2009

 

HGS lupus drug sustained benefits for 4 years 6/11/2009

  CORRECTED - CORRECTED-UPDATE 2-Human Genome says lupus drug... 6/11/2009

UPDATE 3-Human Genome says lupus drug shows positive results 6/11/2009

Human Genome Sciences Announces Completion of Enrollment in... 6/19/2009

Human Genome Sciences to Host July 20 Conference Call to... 7/1/2009

 

 

 

 

Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus

July 1, 2009 7:00 AM ET   All PR Newswire news ROCKVILLE, Maryland, July 1 /PRNewswire-USNewswire/ -- Human Genome Sciences, Inc. HGSI today announced that it expects to have top-line results available on Monday, July 20, from BLISS-52, the first of two pivotal Phase 3 clinical trials of BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) in systemic lupus erythematosus (SLE).
 http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO
Senior management will host a conference call to discuss the results on Monday, July 20, 2009 at 8:15 AM Eastern. The BLISS-52 data will be submitted for full presentation at an appropriate scientific meeting.
Investors may listen to the call by dialing 888-632-5010 or 913-312-0402, passcode 8364417, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-203-1112 or 719-457-0820, confirmation code 8364417.
This conference call also will be webcast and may be accessed at www.hgsi.com. Investors interested in listening to the live webcast should log on before the conference call begins in order to download any software required. The archive of the conference call will remain available for several days.
The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.
HGS, Human Genome Sciences, BENLYSTA and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

 


 

Daily Chart



Weekly Chart

 



Corporate Headquarters

Human Genome Sciences, Inc.
14200 Shady Grove Road
Rockville, MD 20850-3338
Phone: (301) 309-8504
Fax: (301) 309-8512

 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
HGSI
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for HGSI
PostSubject
#636   Bought Out ! TerribleTwit 07/17/14 09:20:50 AM
#635   Dead GDCT CAPITAL 03/20/14 10:18:29 AM
#634   anyone get settlement on their shares yet? Windrider 08/30/12 10:10:07 PM
#633   SC TO-T/A 1 d391341dsctota.htm AMENDMENT NO. 13 TO Pick _M_Low 08/06/12 03:08:30 PM
#632   UNITED STATES Pick _M_Low 08/06/12 03:07:39 PM
#631   8-K 1 d389208d8k.htm FORM 8-K Pick _M_Low 08/06/12 03:06:21 PM
#630   The chart almost looks like a buy out Penny Roger$ 07/16/12 08:19:00 PM
#629   HGSI agrees to takeover by GSK. Silvr Surfr 07/16/12 09:41:25 AM
#628   HGSI looks like the GSK bids coming to rarefind 07/16/12 08:56:01 AM
#627   ~ Monday! $HGSI ~ Q2 Earnings alerted as Penny Roger$ 07/16/12 08:29:58 AM
#626   14$ parabolicplease 07/15/12 10:27:55 PM
#625   Exclusive: Celgene mulls Human Genome Sciences bid - source rarefind 07/07/12 04:39:15 PM
#624   15-17 bucks a share coming, strong buy......rareF rarefind 07/06/12 09:16:43 AM
#623   Adam Feuerstein ?@adamfeuerstein louisa 05/31/12 01:11:54 PM
#622   German gatekeepers nix GSK's lupus drug Benlysta chmcnfunds 05/03/12 01:00:13 PM
#621   18-20 bucks gets the deal done.GSK can afford rarefind 04/21/12 10:05:45 AM
#620   Moving into SGMO after I sell this, they gamesetmatch101 04/19/12 02:45:46 PM
#619   1. GSK puts Human Genome Sciences in play chmcnfunds 04/19/12 01:47:32 PM
#618   guy adami just stated on " fast money buzz lightyear 04/19/12 12:55:09 PM
#617   You go, HGSI!!! I am impressed MoneyBags231 04/19/12 12:46:02 PM
#616   So true. I weighed the risk/return of holding postyle 04/19/12 12:32:14 PM
#615   errrr, that would be wise woman, LOL Flobewan 04/19/12 12:29:40 PM
#614   errrr, that would be wise woman, LOL Flobewan 04/19/12 12:26:19 PM
#613   Wise man, cant look a 100% gainer in TerribleTwit 04/19/12 12:12:05 PM
#612   anybody expecting gap close today? lol cicimici83 04/19/12 12:06:42 PM
#611   CNBC.com Article: Human Genome Stock Up 100% as buzz lightyear 04/19/12 12:06:38 PM
#610   Still waiting on (INO) to pounce ~~~ TerribleTwit 04/19/12 11:34:49 AM
#609   i think this article is not considering the buzz lightyear 04/19/12 10:49:17 AM
#608   Here's to hoping others pharms pounce. thought you buzz lightyear 04/19/12 10:10:11 AM
#607   It may be that I left money on Flobewan 04/19/12 09:34:16 AM
#606   (This story has been posted on buzz lightyear 04/19/12 09:32:42 AM
#605   Yep, I actually sold the rest I had. Flobewan 04/19/12 09:29:47 AM
#604   I think you did a smart thing Flobewan,,,,, TerribleTwit 04/19/12 09:26:55 AM
#603   16.5 m traded pre ..... holy crap ! TerribleTwit 04/19/12 09:22:00 AM
#602   Double 'Day' , you are going to be TerribleTwit 04/19/12 09:15:11 AM
#601   They will probably get it for $16 /share... TerribleTwit 04/19/12 09:11:49 AM
#600   Owned this puppy at .46 ! WOW ~~~ TerribleTwit 04/19/12 09:08:58 AM
#599   6:25AM Human Genome trades above $14 pre-market after surf1944 04/19/12 08:54:45 AM
#598   Nice. Holdem for the settled amount IMO buzz lightyear 04/19/12 08:54:24 AM
#597   I'm freaking out, sold some, am now holding freebies Flobewan 04/19/12 08:48:08 AM
#596   OOOOPsss Got the offer date wrong - it NotRichYet2 04/19/12 08:42:07 AM
#595   just surpassed 9,220,963 share volume in pre-market buzz lightyear 04/19/12 08:38:41 AM
#594   bidding is increasing. the bid book has gone buzz lightyear 04/19/12 08:36:46 AM
#593   I got the 8 buck calls, talk about Doubleday 04/19/12 08:29:08 AM
#592   Based on the UNSOLISITED buyout offer at $13 NotRichYet2 04/19/12 08:13:15 AM
#591   I held on to some, but had to Flobewan 04/19/12 08:12:32 AM
#590   GSK bid 13 dollars a share,hgsi turned it rarefind 04/19/12 08:11:31 AM
#589   they may have refused the offer, but they buzz lightyear 04/19/12 08:10:47 AM
#588   5.3M shares traded by 8:05 AM chmcnfunds 04/19/12 08:08:31 AM
#587   Human Genome surges 99% after rejecting GSK bid. chmcnfunds 04/19/12 08:07:09 AM
PostSubject